Mind Medicine (MindMed) Inc. Announces Pricing of $225 Million Public Offering
Denium Therapeutics, Inc - Common Shares (MNMD)
Company Research
Source: Business Wire
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the pricing of an underwritten public offering of 18,375,000 common shares, without par value, at a public offering price of $12.25 per common share. The gross proceeds to MindMed from the offering, before deducting underwriting discounts, commissions, and other offering-related expenses, are expected to be approximately $225 million. In addition, MindMed has granted the underwriters an option for a period of 30 days to purchase up to an additional 2,756,250 common shares at the public offering price, less underwriting discounts and commissions. All of the common shares are being offered by MindMed.MindMed intends to use the net proceeds from this offering to fund the research and development of its product candidates and working capital and general c
Show less
Read more
Impact Snapshot
Event Time:
MNMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MNMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MNMD alerts
High impacting Denium Therapeutics, Inc - Common Shares news events
Weekly update
A roundup of the hottest topics
MNMD
News
- Assessing Mind Medicine (MNMD) Valuation After A Strong Year Of Share Price Momentum [Yahoo! Finance]Yahoo! Finance
- Mind Medicine (MindMed) (NASDAQ:MNMD) had its "buy" rating reaffirmed by analysts at Needham & Company LLC.MarketBeat
- Wall Street Thinks This 1 Psychedelic Stock Can Gain 335% in 2026 [Yahoo! Finance]Yahoo! Finance
- Mind Medicine (MindMed) (NASDAQ:MNMD) is now covered by analysts at Jones Trading. They set a "buy" rating and a $61.00 price target on the stock.MarketBeat
- Psychedelics stocks could benefit from marijuana rescheduling: Jefferies [Seeking Alpha]Seeking Alpha
MNMD
Earnings
- 11/6/25 - Miss
MNMD
Sec Filings
- 1/12/26 - Form 8-K
- 12/29/25 - Form 4
- 12/29/25 - Form 4
- MNMD's page on the SEC website